Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CPN1 | P15169 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808436 | 1.00 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28243237 | 0.91 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL6298061 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MAPTHTTNPSR1CPN1 | |
| SCHEMBL11109035 | 0.85 | PARP1 (0.49) | ALDH1A1MAPTHTTNPSR1CTSA | |
| SCHEMBL5021484 | 0.84 | CPN1 (0.46) | ALDH1A1CPN1CPB2CTSAGAA | |
| SCHEMBL1492705 | 0.83 | CTSK (0.46) | ALDH1A1CPN1CPB2CTSA | |
| SCHEMBL27996917 | 0.83 | CPN1 (0.49) | ALDH1A1CPN1CPB2CTSAGAA | |
| SCHEMBL15270484 | 0.82 | MMP8 (0.44) | ALDH1A1MAPTCTSAGAA | |
| SCHEMBL7112200 | 0.82 | ALDH1A1 (0.49) | ALDH1A1MAPTHTTNPSR1GAA | |
| SCHEMBL1801772 | 0.81 | AKR1C3 (0.52) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427417-B1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC (CA) | 2013-10-09 | — | — | EP | claimed |
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-19 | — | — | US | claimed |
| EP-2427417-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | claimed |
| WO-2025085554-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085564-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2024-10-08 | — | — | US | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS, INCORPORATED | 2023-04-27 | — | — | US | disclosed |
| US-11479561-B2 | Tetrahydroisoquinoline derivatives | CYTOKINETICS, INCORPORATED (US) | 2022-10-25 | — | — | US | disclosed |
| EP-4032877-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Cytokinetics, Incorporated (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3413892-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6025388-A | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids | ALLERGAN SALES, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| US-5489584-A | ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS; TREATING SKIN DISORDER, CARDIOVASCULAR DISORDER | ALLERGAN, INC. (US) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | GLS, REN, PTP4A3 | AKR1C3 42/4885AKR1C2 164/4885AKR1C1 309/4885 |
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | TNNC1, TNNI3, TNNT2 | AKR1C3 3072/4885AKR1C2 2688/4885AKR1C1 2551/4885 |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | CDKL1, CDK4, CDKL3 | AKR1C3 2082/4885AKR1C2 1653/4885AKR1C1 1874/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | AKR1C3 1469/4885AKR1C2 2174/4885AKR1C1 2151/4885 |
| US-11479561-B2 | Tetrahydroisoquinoline derivatives | TNNC1, TNNI3, TNNT2 | AKR1C3 3072/4885AKR1C2 2688/4885AKR1C1 2551/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | AKR1C3 1469/4885AKR1C2 2174/4885AKR1C1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.